Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHIMERIX INCCMRX · Entity 80651 | Director | May 17, 2018 | May 21, 2018 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | November 17, 2021 | November 22, 2021 |
| Jasper Therapeutics, Inc.AMHCU · Entity 7588 | Director | November 19, 2019 | November 19, 2019 |
| Kindred Biosciences, Inc.KIN · Entity 135544 | Director | January 20, 2021 | January 22, 2021 |
| SOLENO THERAPEUTICS INCSLNO · Entity 46432 | Director | June 06, 2024 | June 10, 2024 |
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | June 25, 2018 | June 27, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHIMERIX INC
Report date May 17, 2018 · Filed May 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees | 123,167 |
Reported balance
After 2018-05-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-05-17 · Sale · Disposed 30,000 · Balance 123,167 F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees | 108,167 |
Reported balance
After 2018-05-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-05-18 · Sale · Disposed 15,000 · Balance 108,167 F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 12,905 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,905 |
Filing footnotes · ownership attribution and instrument terms
F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
HYPERION DEFI, INC.
Report date November 17, 2021 · Filed November 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 382,706 |
Reported balance
After 2021-11-17 transaction · row 1
1 source rowRow 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 382,706 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17 | Direct | 9,653 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Jasper Therapeutics, Inc.
Report date November 19, 2019 · Filed November 19, 2019
This filing explicitly reported no securities owned.
Kindred Biosciences, Inc.
Report date January 20, 2021 · Filed January 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19 | Direct | 49,000 |
Reported balance
After 2021-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-20 · Grant · Acquired 49,000 · Balance 49,000 F1: The option will vest in four equal quarterly installments from the option grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in four equal quarterly installments from the option grant date.
SOLENO THERAPEUTICS INC
Report date June 06, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 193,066 |
Reported balance
After 2024-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 6,500 · Balance 193,066 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 21,789 |
Reported balance
Holding disclosure · report date 2024-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 21,789 F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.
F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee.
Tonix Pharmaceuticals Holding Corp.
Report date June 25, 2018 · Filed June 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Ernest and Mildred Mario Revocable Trust | 50,000 |
Reported balance
After 2018-06-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-06-25 · Purchase · Acquired 16,500 · Balance 50,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 62,884 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 4,908 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000730 · form4-06172019_040624.xml · derivative · entry 6 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F8 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F3 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F3 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000730 · form4-06172019_040624.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000730 · form4-06172019_040624.xml · derivative · entry 5 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 Underlying: Common Stock · 484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 485 shares on June 13, 2020 and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000730 · form4-06172019_040624.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F2 · balance_after: The amount of shares beneficially owned following the reported transaction also includes (i) 324 shares previously reported as held by spouse and indirectly owned, (ii) an aggregate of 5,676 shares that were acquired prior to the reporting person becoming a director of the Company in August 2007 and were inadvertently omitted from the reporting person's initial Form 3 filing and (iii) an aggregate of 720 shares that were acquired in December 2007 and were never reported on a Form 4 filing. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 17:36 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-016667 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is June 10, 2019) or the day before the 2019 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000663 · form4-06052019_040615.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 Underlying: Common Stock · 4,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | OtherCommon Stock | 2,908 | $85.97 | $250,000.76 |
DisclosureSEC source: 0001415889-19-000284 · form4-03072019_040301.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 4,908 F1 · kind: Reflects the transfer of shares pursuant to an exemption under Rule 16a-13 to the Ernest Mario 15-year Residence Trust (the "GRAT"), for which the reporting person is the trustee, in exchange for cash pursuant to the terms of the GRAT. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | OtherCommon Stock | 2,908 | $85.97 | $250,000.76 |
DisclosureSEC source: 0001415889-19-000284 · form4-03072019_040301.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,005 F1 · kind: Reflects the transfer of shares pursuant to an exemption under Rule 16a-13 to the Ernest Mario 15-year Residence Trust (the "GRAT"), for which the reporting person is the trustee, in exchange for cash pursuant to the terms of the GRAT. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | PurchaseCommon Stock | 2,000 | $89.99 | $179,980.00 |
DisclosureSEC source: 0001415889-19-000168 · form4-02142019_040201.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 2,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $89.985 to $90.00, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for the purpose of Section 16 or for any other purpose. These shares are held in the Ernest Mario 15-Year Residence Trustee, for which the reporting person is the trustee. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:42 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0001250853-19-000041 · primary_doc.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: The option will vest in four equal quarterly installments from the option grant date. Read SEC document |
| January 14, 2019 Filed Feb 14, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GiftCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000168 · form4-02142019_040201.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,913 Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 16:48 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 8,600 | $0.00 Strike: $59.06 | $0.00 |
DisclosureSEC source: 0001415889-18-001812 · form4-12202018_011232.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,600 shares Expires 2023-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 16:48 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 8,600 | $59.06 | $507,873.00 |
DisclosureSEC source: 0001415889-18-001812 · form4-12202018_011232.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $59.06 | $0.00 |
DisclosureSEC source: 0001415889-18-001688 · form4-11282018_041101.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 Underlying: Common Stock · 10,000 shares Expires 2023-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 10,000 | $59.06 | $590,550.00 |
DisclosureSEC source: 0001415889-18-001688 · form4-11282018_041101.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 18:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Exercise / conversionStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001250853-18-000135 · primary_doc.xml · derivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 44,000 shares, became exercisable in four equal quarterly installments following the date of grant, which was January 8, 2016. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 18:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Exercise / conversionStock Option (right to buy) · Derivative | 833 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001250853-18-000135 · primary_doc.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 833 shares Expires 2023-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable as to 5,000 shares beginning on August 29, 2014, which was the first anniversary of the date on which the option was granted, and the remaining shares vested in equal monthly installments over the following 36 months. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 18:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Exercise / conversionCommon Stock | 44,000 | $3.45 | $151,800.00 |
DisclosureSEC source: 0001250853-18-000135 · primary_doc.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 18:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Exercise / conversionCommon Stock | 833 | $1.37 | $1,141.21 |
DisclosureSEC source: 0001250853-18-000135 · primary_doc.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 12,000 | $92.32 | $1,107,888.00 |
DisclosureSEC source: 0001415889-18-001260 · form4-08132018_040801.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,413 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $92.310 to $92.325, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 18:12 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 4,465 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001638599-18-000822 · doc4_5553.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,465 Underlying: Common Stock · 4,465 shares Expires 2028-07-24 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of July 24, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 18:12 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 4,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000822 · doc4_5553.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,770 F1 · shares: Represents restricted stock units that vest on the earlier of July 24, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 16,500 | $4.48 | $73,920.00 |
DisclosureSEC source: 0001615774-18-005782 · s111042_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 19:48 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001250853-18-000092 · primary_doc.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The option will vest in four quarterly installments following the grant date. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000951 · form4-06182018_040619.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000951 · form4-06182018_040619.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000941 · form4-06152018_010610.xml · derivative · entry 7 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F10 · derivative.exercise_price: The remainder of the restricted stock units will vest on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000941 · form4-06152018_010610.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000941 · form4-06152018_010610.xml · derivative · entry 6 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F9 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 300 shares on June 14, 2019 and 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000941 · form4-06152018_010610.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2018 Filed Jun 13, 2018 17:05 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,606 | $2.04 | $7,356.24 |
DisclosureSEC source: 0000899243-18-016391 · doc4.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,324 Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-18-000941 · form4-06152018_010610.xml · derivative · entry 5 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,266 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F8 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F7 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next stockholder meeting. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000941 · form4-06152018_010610.xml · derivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,454 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F5 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F5 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 17:16 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-005234 · s110814_form4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-12 F1 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 17:05 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 500 | $2.04 | $1,020.00 |
DisclosureSEC source: 0000899243-18-016391 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,718 Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 17:05 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 4,980 | $2.05 | $10,209.00 |
DisclosureSEC source: 0000899243-18-016391 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,218 Read SEC document |
| June 11, 2018 Filed Jun 18, 2018 18:10 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 15,931 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017046 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,931 Underlying: Common Stock · 15,931 shares Expires 2028-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:01 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 14,803 | $2.04 | $30,257.33 |
DisclosureSEC source: 0000899243-18-015955 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,238 Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 16:01 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 4,611 | $2.00 | $9,233.53 |
DisclosureSEC source: 0000899243-18-015955 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,435 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 15:10 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 1,200 | $2.05 | $2,460.00 |
DisclosureSEC source: 0000899243-18-015421 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,824 Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 16:54 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 1,300 | $2.05 | $2,665.00 |
DisclosureSEC source: 0000899243-18-014931 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,624 Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:54 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 500 | $2.05 | $1,025.00 |
DisclosureSEC source: 0000899243-18-014931 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,324 Read SEC document |
| May 29, 2018 Filed May 29, 2018 18:18 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 500 | $2.01 | $1,005.00 |
DisclosureSEC source: 0000899243-18-014306 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,824 Read SEC document |
| May 25, 2018 Filed May 29, 2018 18:18 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 5,000 | $2.05 | $10,250.00 |
DisclosureSEC source: 0000899243-18-014306 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,324 Read SEC document |
| May 21, 2018 Filed May 22, 2018 16:57 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 5,000 | $1.94 | $9,720.00 |
DisclosureSEC source: 0000899243-18-013705 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,324 Read SEC document |
| May 21, 2018 Filed May 22, 2018 16:57 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 25,000 | $1.95 | $48,750.00 |
DisclosureSEC source: 0000899243-18-013705 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,324 Read SEC document |
| May 18, 2018 Filed May 21, 2018 13:34 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 15,000 | $4.81 | $72,142.50 |
DisclosureSEC source: 0001209191-18-031705 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 108,167 F2 · price: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 18, 2018 Filed May 21, 2018 18:26 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 25,000 | $1.90 | $47,500.00 |
DisclosureSEC source: 0000899243-18-013609 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,324 Read SEC document |
| May 17, 2018 Filed May 21, 2018 13:34 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 30,000 | $4.80 | $143,931.00 |
DisclosureSEC source: 0001209191-18-031705 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 123,167 F1 · price: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 16, 2018 Filed May 17, 2018 11:51 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 30,000 | $4.79 | $143,808.00 |
DisclosureSEC source: 0001209191-18-030788 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 153,167 F1 · price: The range of sale prices received is $4.69 to $4.865. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.